Takeda Pharmaceutical TAK
$21.77 +$0.36 (+1.68%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $22.09 +1.47%
Open$21.82
Prev close$21.41
Day range$21.74 – $22.07
Volume3.80M
Market cap$69.76B
P/E (TTM)311.0
Dividend yield1.44%
Earnings
Average move on report day±2.8%last 16 reports
Closed higher7 of 1644% of the time
Best reaction+2.9%
Worst reaction-7.7%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2027/Q2 | 29 Oct 2026 | None | ±6.1% | -0.69% | Within range |
| 2027/Q1 | 30 Jul 2026 | None | ±5.8% | -2.82% | Within range |
| 2026/Q4 | 13 May 2026 | None | ±10.4% | +1.34% | Within range |
| 2026/Q3 | 29 Jan 2026 | None | ±6.1% | +2.88% | Within range |
| 2026/Q2 | 30 Oct 2025 | None | ±12.7% | -3.92% | Within range |
| 2026/Q1 | 30 Jul 2025 | Pre Market | ±7.6% | -5.03% | Within range |
| 2025/Q4 | 8 May 2025 | Pre Market | ±5.3% | -5.25% | Within range |
| 2025/Q3 | 30 Jan 2025 | Pre Market | ±5.3% | +2.93% | Within range |
| 2025/Q2 | 31 Oct 2024 | None | ±10.2% | +0.36% | Within range |
| 2025/Q1 | 31 Jul 2024 | Pre Market | – | +1.69% | – |
| 2024/Q4 | 9 May 2024 | None | ±12.1% | +2.37% | Within range |
| 2024/Q3 | 1 Feb 2024 | Pre Market | ±4.1% | -1.51% | Within range |
| 2024/Q2 | 26 Oct 2023 | None | ±5.3% | -7.72% | Bigger than priced |
| 2024/Q1 | 27 Jul 2023 | None | ±6.7% | +1.04% | Within range |
| 2023/Q4 | 11 May 2023 | None | ±6.7% | -4.83% | Within range |
| 2023/Q3 | 2 Feb 2023 | None | ±6.6% | -0.69% | Within range |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Where the revenue comes from
Quarter 2027/Q1
By business line
Fundamentals
Latest reported quarter: Q2, ended Sep 2026 · reported in JPY
Revenue¥1.19T+6.7% YoY
Operating profit¥285.14B+195.7% YoY
Net profit¥192.46B+1,740.9% YoY
Diluted EPS¥59.49+1,619.5% YoY
Free cash flow¥248.55B-23.6% YoY
Operating cash flow¥304.27B
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin65.8%
Operating margin14.3%
Net margin0.9%
Return on equity0.6%
Return on assets0.3%
Return on invested capital1.1%
Current ratio1.15
Liabilities / assets51.4%
Cash & investments¥454.40B
Total debt¥4.58T
Net cash (debt)-¥4.12T
Free cash flow / sales9.2%
No comments yet — be the first to weigh in on TAK.
Sign in to join the discussion.